BioLife Solutions(BLFS)

Search documents
BioLife Solutions to Report Second Quarter 2024 Financial Results and Business Update on August 8, 2024
Prnewswire· 2024-07-25 20:03
BOTHELL, Wash., July 25, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's second quarter 2024 financial results will be released after market close on Thursday, August 8, 2024. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company's financi ...
What Makes BioLife Solutions (BLFS) a Good Fit for 'Trend Investing'
ZACKS· 2024-07-12 13:52
When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done. Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate re ...
BioLife Solutions Introduces the CellSeal CryoCase™ at International Society for Cell & Gene Therapies (ISCT) Conference in Vancouver
Prnewswire· 2024-05-29 12:04
New container developed for the needs of cell and gene therapy (CGT) primary packaging to replace cryopreservation bags with a fracture resistant, rigid construction built for both manual use and closed-system automation. BOTHELL, Wash., May 29, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of bioproduction tools and services for the cell and gene therapy (CGT) and broader biopharma markets, today announced the introduction of the CryoCase, an addition to its CellSeal produ ...
BioLife Solutions(BLFS) - 2024 Q1 - Quarterly Report
2024-05-10 21:11
4J Table of Contents award of $6.8 million is being expensed on a straight-line basis over the grant date to the vesting date of December 31, 2024, excluding $1.6 million of expense recognized in 2023 to reflect accelerations in the vesting period of certain awards. On March 8, 2024, the Company granted 239,464 shares of market-based stock to its executives in the form of restricted stock. The shares granted contain a market condition based on TSR. The TSR market condition measures the Company's performance ...
BioLife Solutions(BLFS) - 2024 Q1 - Earnings Call Transcript
2024-05-10 00:36
Start Time: 16:30 January 1, 0000 5:02 PM ET BioLife Solutions, Inc. (NASDAQ:BLFS) Q1 2024 Earnings Conference Call May 09, 2024, 16:30 PM ET Company Participants Rod de Greef - Chairman and CEO Troy Wichterman - CFO Garrie Richardson - Chief Revenue Officer Conference Call Participants Paul Knight - KeyBanc Hannah Hefley - Stephen Inc. Matthew Stanton - Jefferies Matt Hewitt - Craig-Hallum Capital Group Thomas Flaten - Lake Street Capital Operator Welcome to the BioLife Solutions First Quarter 2024 Financi ...
BioLife Solutions, Inc. (BLFS) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research· 2024-05-09 23:05
BioLife Solutions, Inc. (BLFS) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.32 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 26.92%. A quarter ago, it was expected that this company would post a loss of $0.36 per share when it actually produced a loss of $0.30, delivering a surprise of 16.67%.Over the last four quarters, the company has ...
BioLife Solutions(BLFS) - 2024 Q1 - Quarterly Results
2024-05-09 20:09
3303 Monte Villa Parkway, Suite 310 | Bothell, WA 98021 USA | 866.424.6543 phone | BioLifeSolutions.com BioLife Solutions Reports First Quarter 2024 Financial Results Cell Processing revenue increased 10% sequentially to $16.2 million GAAP gross margin of 38% and net loss of $10.2 million Non-GAAP adjusted gross margin expands from 40% to 53% and adjusted EBITDA of $3.6 million or 13% ex-GCI freezers Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash. (May 9, 2024) – BioLife Solutions, Inc ...
BioLife Solutions Announces the Divestiture of its Stirling Freezer Business
Prnewswire· 2024-04-18 12:05
BOTHELL, Wash., April 18, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") and the broader biopharma markets, today announced that it has completed the divestiture of its wholly owned subsidiary Global Cooling, Inc. ("GCI" or "Stirling"). Roderick de Greef, Chairman and CEO, commented, "After a thorough and extensive process, we're pleased to have completed t ...
BioLife Solutions to Present at TD Cowen and Key Bank Investor Conferences
PRNewsWire· 2024-03-04 13:03
BOTHELL, Wash., March 4, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced that Roderick de Greef, Chief Executive Officer, and Troy Wichterman, Chief Financial Officer, will present and meet with current and prospective investors at the following March Investor Conferences.TD Cowen 44th Annual Healthcare Conference (Boston, MA): March 5-6th1 ...
BioLife Solutions(BLFS) - 2024 Q4 - Earnings Call Transcript
2024-03-01 03:06
Rod de Greef Paul Knight Hey, thanks. Good afternoon. Maybe Rod, just first on the freezer sale. Appreciate the commentary in the prepared comments. Appreciate kind of what you just outlined to Paul's question. But I guess kind of how confident -- you've got two LOIs, sounds like this all hopefully be over in two months. But just how confident are you that this will all be concluded in the next couple of months? And then I heard you mention some maybe outlays related to these transactions. Is there any way ...